Rational Drug Design Europe Summit

Memo

The Rational Drug Design Europe Summit is the dedicated forum bringing together structural biologists, biophysicists, medicinal chemists, drug discovery scientists, computational chemists, and AI drug discovery leaders committed to transforming the future of drug development. As biopharma organizations face increasing pressure to identify high-value targets, reduce attrition rates and accelerate timelines to the clinic, rational drug design has become a cornerstone of modern discovery strategies. By leveraging deep insights into molecular interactions and protein structure, researchers can make more informed decisions earlier in the discovery process, improving efficiency and increasing confidence in candidate selection. Advances in structural biology, orthogonal biophysics, and AI are enabling researchers to better understand disease mechanisms, identify druggable targets, validate molecular interactions, and design molecules with greater precision. Together, these technologies are accelerating drug discovery, improving decision-making, and reducing development risk. Despite growing innovation across the field, Europe has lacked a dedicated meeting focused on the intersection of rational drug design, structural biology, biophysics and AI-enabled drug discovery. The Rational Drug Design Europe Summit has been established to unite experts across disciplines, facilitate knowledge exchange and advance next-generation drug discovery strategies. URLs:  Tickets: https://go.evvnt.com/3853862-2?pid=5569 Brochure: https://go.evvnt.com/3853862-3?pid=5569    Date and Time: Wed, 13 Jan 2027 08:00 - Thu, 14 Jan 2027 17:00   Venue details: Park Plaza Victoria Amsterdam, 1-5 Damrak, Amsterdam, Noord-Holland, 1012 LG, Netherlands   Prices:Drug Developer Pricing - Conference Pass: EUR 2449.00,Academic Pricing - Conference Pass: EUR 2149.00,Service Provider Pricing - Conference Pass: EUR 3449.00   Speakers: Alain Beck, Senior Director Biologics CMC and Developability, Pierre Fabre, Alexey Rak, Head of Bio Structure and Biophysics, Sanofi, Ansgar Wegener, Director, Structural Biology and Biophysics, Merck Healthcare, Beatrice Li, Team Lead of Protein Science and Structural Biology, Confo Therapeutics, Christian Ottmann, Founder and Chief Executive Officer, Ambagon Therapeutics, David Brown, Senior Director Structural Biology and Biophysics, Vertex Pharmaceuticals, Gustavo Arruda Bezerra, Associate Director, Structural Biology, Bicycle Therapeutics, Ilaria Ferlenghi, Associate Director, Senior Scientific Leader Protein Structure and Biochemistry, Vx Discovery Tech, GSK, Jonathan Hopper, Founder and Vice President - Platforms, OMass Therapeutics, Klaus Orlinger, Chief Scientific Officer, VALANX Biotech, Kirill Pevzner, Founder and Chief Technical Officer, Protai, Krzysztof Brzózka, Chief Scientific Officer, Ryvu Therapeutics, Pravin Mahajan, Associate Director, Discovery Technologies, Astex Pharmaceuticals, Radoslav Enchev, Group Leader, The Francis Crick Institute, Robert Dagil, Director, Bispecific Antibodies and CMC, VAR2 Pharmaceuticals, Taiana Maia De Oliveira, Director, Biophysics, AstraZeneca, Victor Guallar, ICREA Professor and Group Leader, Barcelona Supercomputing Group